• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Two Firms Reiterate Buy Rating for GW Pharmaceuticals

December 6, 2017

 

Two different firms have recently reiterated their buy ratings for shares of GW Pharmaceuticals Plc (NASDAQ:GWPH) closely following the company's filing of year-end financial and operational results. The two analysts' price targets are over $40 apart, so we wanted to fill in existing and prospective investors on the recent development. 

 

Cowen & Co.
 

Phil Nadeau, the managing director and senior research analyst on the biotechnology team at Cowen & Co., reiterated his buy rating on shares of GWPH. Higgins' price target for the stock is $165.00 per share. At the time of writing this, shares of GW Pharmaceuticals were trading at $111.81 per share, representing over 47% potential upside. 

 

 

Nadeau's $165 price target is just south of the average analyst price target of $208, according to TipRanks. The $165 price target is also far below the price target from Elemer Piros at Cantor Fitzgerald.

 

Cantor Fitzgerald

 

Elemer Piros, Ph.D., a healthcare and biotechnology analyst from Cantor Fitzgerald, also reiterated his buy rating on shares of GWPH. Piros' price target for the stock is $208.00 per share. At the time of writing this, shares of GW Pharmaceuticals were trading at $111.81 per share, representing over 86% potential upside.

 

According to TheFly, "The analyst notes that before the end of 2017, the FDA will announce whether GW's New Drug Application filing has been accepted for review."

 

This is the highest price target out of the three analysts covering the company. 

 

For more cannabinoid biotech stocks, check out our biotech marijuana stock database. Be sure to subscribe to one or more of our free newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram

 

D/M/O

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.